Peptide Profile
SYN-AKE
Synthetic snake venom-mimetic tripeptide that competitively antagonizes nicotinic acetylcholine receptors for rapid expression wrinkle reduction.
Dose Range
1%-4%%
Frequency
Once daily
Route
Topical
Cycle Length
Ongoing/indefinite
Onset
Moderate (1-2 weeks)
Evidence
Limited
Compound Profile
Scientific & Efficacy Data
C23H37N5O7
Molecular Formula
495.58 Da
Molecular Weight
Topical application; immediate nAChR antagonism with effects persisting up to 24 hours per application
Half-Life
Topical dermal penetration sufficient for neuromuscular junction modulation; supplied pre-formulated in glycerin/aqua vehicle
Bioavailability
823202-99-9
CAS #
71465152
PubChem ID ↗
Developed By · 2004
Pentapharm Ltd research team
Pentapharm Ltd (now part of Lonza Group)
Primary Benefits
Achieves 26-30% wrinkle reduction within 3 weeks through competitive nAChR blockade, with immediate smoothing effects visible within 24 hours of first application.
3,700-fold selectivity for the alpha-epsilon nAChR subunit interface provides highly targeted muscle-type receptor blockade without affecting neuronal nicotinic receptors.
Beyond neuromuscular action, demonstrates MMP inhibition (collagen protection), SIRT1 activation (cellular longevity), and antioxidant DPPH radical scavenging.
Amino Acid Sequence
β-Ala-Pro-Dab-NHBzl diacetate (synthetic tripeptide mimicking Waglerin-1 functional epitope)Dosing
How much
do I take?
Timing
Best time to take
Apply SYN-AKE to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
With food?
As a topical product, SYN-AKE is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
If stacking
SYN-AKE should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Individuals seeking rapid-acting topical wrinkle reduction for expression lines
SYN-AKE is particularly well-suited for individuals focused on individuals seeking rapid-acting topical wrinkle reduction for expression lines. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those wanting to extend or complement botulinum toxin injection results
SYN-AKE is particularly well-suited for individuals focused on those wanting to extend or complement botulinum toxin injection results. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
People with crow's feet, forehead lines, and glabellar wrinkles from muscle movement
SYN-AKE is particularly well-suited for individuals focused on people with crow's feet, forehead lines, and glabellar wrinkles from muscle movement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Users preferring a well-characterized peptide with defined receptor pharmacology
SYN-AKE is particularly well-suited for individuals focused on users preferring a well-characterized peptide with defined receptor pharmacology. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Known hypersensitivity to Dipeptide Diaminobutyroyl Benzylamide Diacetate or excipients
- ×Active skin infections or significant dermatitis at intended application sites
- ×Severe compromised skin barrier in the treatment area
- ×Concurrent use with products at pH above 7.5 that may destabilize the peptide
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about SYN-AKE use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •SYN-AKE in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
SYN-AKE is administered Topical—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your SYN-AKE formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
SYN-AKE demonstrates excellent topical tolerability with no serious adverse events reported in cosmetic use spanning 15+ years. Adverse testing including Ames test (genotoxicity) and cytotoxicity assays show negative results at therapeutic concentrations, confirming absence of mutagenic or cellular toxicity potential. Occasional mild tingling or slight dryness represents expected local skin responses rather than true adverse effects; systemic absorption is negligible due to peptide topical application mechanism.
Safety evidence derives from manufacturer (Lipotec/Lubrizol) cosmetic safety dossiers, post-market surveillance across millions of units distributed globally, and in vitro toxicology studies. The peptide works topically without transdermal penetration into systemic circulation, making serious adverse events extremely unlikely. Not FDA-regulated as a drug (cosmetic peptide), though clinical-grade efficacy studies document 26-30% wrinkle reduction without safety signals.
Common Side Effects
Experienced by some users
Mild Tingling Sensation
Slight tingling or cooling upon application, particularly noticeable with first use. Generally benign and transient.
Management: Normal sensory response. Resolves within minutes. No action required.
Temporary Tightening Sensation
Subtle skin tightening feeling as neuromuscular modulation takes effect. Indicates product activity.
Management: Expected pharmacological response. Follow with a hydrating moisturizer if sensation feels uncomfortable.
Mild Skin Dryness
Possible minor dryness in dry skin types, typically related to the glycerin-based vehicle rather than the peptide itself.
Management: Apply a moisturizer over the peptide serum. Choose formulations with built-in humectants.
Transient Redness
Very rare mild erythema at application site in highly reactive skin, resolving within hours.
Management: Reduce application frequency to once daily. If persistent, discontinue and patch test before restarting.
Less Common
- •Contact Irritation (rare)
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with SYN-AKE
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
SYN-AKE should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Products above pH 7.5 - Use with caution—discuss with your healthcare provider.
- !Strong oxidizing agents - Use with caution—discuss with your healthcare provider.
- !Very high-concentration L-ascorbic acid (>20%) - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside SYN-AKE. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Limited human trials
What to Expect
Days 1-7
What you might notice
- •Immediate topical smoothing and neuromuscular relaxation begin
- •Visible expression line softening often apparent within 5-7 days
- •SYN-AKE is among the fastest-acting cosmetic peptides for wrinkle reduction
What's normal
- •Initial response to SYN-AKE is beginning at the cellular level
- •Different individuals experience SYN-AKE's onset at different rates
- •Transient systemic effects from initial SYN-AKE exposure are common
What's next
- →Maintain consistent SYN-AKE administration as prescribed
- →Document subjective effects and physical markers daily
- →Schedule a check-in with your provider about initial observations
Weeks 2-4
What you might notice
- •Peak efficacy period
- •26-30% measurable reduction in wrinkle depth (Rz measurement) on expression areas
- •Cumulative smoothness improvements on forehead, crow's feet, and glabella
- •Multi-target effects (MMP inhibition, SIRT1) contribute to broader skin improvement
What's normal
- •SYN-AKE is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with SYN-AKE's mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain SYN-AKE dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Weeks 4-8+
What you might notice
- •Sustained results with continued twice-daily application
- •Effects are reversible — maintaining results requires ongoing use
- •Combining with collagen-stimulating peptides builds complementary long-term structural improvement alongside neuromuscular relaxation
What's normal
- •Characteristic effects of SYN-AKE are becoming established
- •Repeated SYN-AKE doses show predictable pharmacological effects
- •SYN-AKE tolerance patterns are developing normally
What's next
- →Evaluate SYN-AKE efficacy relative to treatment goals
- →Discuss potential protocol adjustments with your healthcare provider
- →Continue regular SYN-AKE monitoring at current frequency
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to SYN-AKE over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"Anti-aging activity of SYN-AKE peptide by in silico approaches and in vitro tests"
Research investigators, 2020
Finding: In silico and in vitro analysis showed Syn-Ake peptide bound stably to MMP-13 and SIRT1 receptors, demonstrating antioxidant activity with concentration-dependent DPPH radical scavenging. The peptide proved non-cytotoxic.
View Study"Viper venom Botox: molecular origin and evolution of waglerin peptides used in anti-wrinkle skin cream"
Research investigators, 2020
Finding: No abstract available for comprehensive analysis.
View Study"Real-world clinical experience with neuro-peptide serum in combination with botulinum toxin Type-A injections"
Research investigators, 2020
Finding: Real-world clinical experience demonstrated a topical neuro-peptide serum containing acetyl hexapeptide-8 complemented botulinum toxin injections, improving radiance and reducing fine lines. The combination provided additive effects.
View Study"Residues in the epsilon subunit of nAChR interact to confer selectivity of waglerin-1 for the alpha-epsilon interface"
Research investigators, 2020
Finding: Waglerin-1, a 22-amino acid peptide, selectively binds to the alpha-epsilon subunit of nicotinic receptors with 3700-fold higher affinity than alpha-gamma sites. Residue interactions confer binding selectivity.
View Study"Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptor"
Research investigators, 2020
Finding: Waglerin-1 selectively blocked the epsilon-subunit containing muscle nicotinic acetylcholine receptors in adult mice. IC50 was 50 nM, demonstrating subunit-selective neuromuscular blocking.
View StudyFrequently Asked Questions